President Donald Trump announced his nomination of Dr. Heidi Overton to serve as the next commissioner of the U.S. Food and Drug Administration. Overton, a 37‑year‑old physician with a background in public health, will appear before the Senate Health, Education, Labor and Pensions (HELP) Committee on Thursday for her first public hearing.
Administration’s view
Trump praised Overton as a “rockstar” in his administration, noting her work alongside Secretary Robert F. Kennedy Jr. and former Secretary Dr. Oz on what the White House calls the “most transformative health agenda in history.” The president highlighted her experience overseeing White House health initiatives and her personal battle with type 1 diabetes, saying she understands the challenges faced by patients and biotech innovators.
Nominee’s credentials
Overton earned her medical degree from the University of New Mexico School of Medicine and completed a surgical residency at Johns Hopkins University. She is board‑certified in public health and general preventive medicine. Prior to the nomination she served as deputy assistant for domestic policy in the Trump administration, where she helped shape health‑related executive actions. Her LinkedIn profile lists a Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health and a stint as chief policy officer at the America First Policy Institute, a pro‑Trump think tank.
Potential Senate scrutiny
The HELP Committee is expected to focus on two hot‑button issues: Overton’s support for the administration’s recent executive order that would split the measles‑mumps‑rubella (MMR) vaccine into separate shots, and her stance on medication abortion. Senate Republican Chairman Bill Cassidy (R‑LA) expressed concern about Overton’s limited managerial experience, noting the FDA’s recent loss of more than 4,600 workers since 2024 and ongoing staffing challenges.
Senator Cassidy also questioned Overton’s involvement in the executive order, calling it “nonsensical” and suggesting it raises doubts about her commitment to sound science and children’s health.
Critics weigh in
Dr. Peter Lurie, former FDA official and president of the Center for Science in the Public Interest, labeled Overton’s alignment with the administration’s vaccine‑splitting plan as “fully disqualifying.” He warned that the agency, already strained by workforce reductions, cannot afford a commissioner who needs on‑the‑job training.
Democratic Senator Patty Murray (D‑WA) described Overton as a “far‑right, anti‑abortion extremist” and pledged a no‑vote, citing Overton’s past statements that medication abortions are “dangerous to women.” Murray’s remarks reflect broader Democratic concerns about potential moves to restrict or revoke FDA approval of mifepristone, a medication used to induce abortions.
Policy implications
If confirmed, Overton would oversee the FDA’s $7 billion budget and a staff of roughly 16,000. The agency’s regulatory decisions affect about 20 cents of every consumer dollar. Overton’s nomination comes as the Trump administration pushes Project 2025, a Heritage Foundation‑backed blueprint that seeks tighter restrictions on medication abortion and other health‑policy reforms.
Supporters argue that Overton’s experience in the White House and her personal health journey position her to streamline the review of innovative therapies, including promising cell and gene treatments for type 1 diabetes that have been delayed by the agency’s backlog.
Next steps
The HELP Committee will hold a hearing where senators can question Overton on her policy positions and management plan. Following the hearing, the committee will vote on whether to advance her nomination to the full Senate for confirmation.
Original reporting: El Paso News (HLL/CB) — read the source article.
